0001618835-20-000218.txt : 20200910
0001618835-20-000218.hdr.sgml : 20200910
20200910200439
ACCESSION NUMBER: 0001618835-20-000218
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200908
FILED AS OF DATE: 20200910
DATE AS OF CHANGE: 20200910
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PELLETIER SAUNDRA L
CENTRAL INDEX KEY: 0001251371
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36754
FILM NUMBER: 201169692
MAIL ADDRESS:
STREET 1: C/O EVOFEM BIOSCIENCES, INC.
STREET 2: 12400 HIGH BLUFF DRIVE, SUITE 600
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Evofem Biosciences, Inc.
CENTRAL INDEX KEY: 0001618835
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208527075
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12400 HIGH BLUFF DRIVE
STREET 2: SUITE 600
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 550-1900
MAIL ADDRESS:
STREET 1: 12400 HIGH BLUFF DRIVE
STREET 2: SUITE 600
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Neothetics, Inc.
DATE OF NAME CHANGE: 20140905
4
1
wf-form4_159978266397349.xml
FORM 4
X0306
4
2020-09-08
0
0001618835
Evofem Biosciences, Inc.
EVFM
0001251371
PELLETIER SAUNDRA L
C/O EVOFEM BIOSCIENCES, INC.
12400 HIGH BLUFF DRIVE, SUITE 600
SAN DIEGO
CA
92130
1
1
0
0
Chief Executive Officer
Common Stock
2020-09-08
4
S
0
122500
3.26
D
360888
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.09 to $3.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
The total amount of securities beneficially owned includes 4,303 shares of common stock the reporting person purchased in accordance with the 2019 ESPP based on 85% of the closing stock price on June 12,2020, the last trading day of the purchase period.
/s/ Justin J. File, attorney-in-fact
2020-09-10